title: The in vitro treatment with vitamin D3 is ineffective on the expression of PKC isoenzymes, but decreases further the impaired production of IL-2 in the T lymphocytes of SLE patients.
abstract: The objective of the study was to investigate the possibility whether the in vitro treatment with vitamin D3 can restore the impaired expression of protein kinase C (PKC) isoenzymes and IL-2 production in the lymphocytes of patients with systemic lupus erythematosus (SLE). Purified T lymphocytes from 14 patients with SLE and 13 healthy controls were cultured for 48 h in the presence and absence of 1 and 100 nM doses of vitamin D3. The expressions of various PKC isoenzymes were tested by Western blot analysis, and the amounts of various cytokines were detected by ELISA in the culture supernatants. Neither the low (1 nM) nor the high (100 nM) doses of vitamin D3 (1α,-25-dihydroxyvitamin) applied in vitro for 48 h were able to restore the decreased expression of PKC isoenzymes in the T cells of SLE patients. However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon γ and TNF α in the culture supernatants of both groups. As the low production of IL-2 is one of the main pathologic features of SLE, we recommend to avoid the use of high doses of vitamin D3 for treatment of lupus patients with vitamin D3 deficiency.
authors.affiliation: Department of Physiology, University of Debrecen, Debrecen, Hungary.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Czifra
authors.forename: Balázs
authors.initials: B
authors.lastname: Tóth
authors.forename: Ildikó
authors.initials: I
authors.lastname: Kovács
authors.forename: Tamás
authors.initials: T
authors.lastname: Bíró
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Griger
authors.forename: Sándor
authors.initials: S
authors.lastname: Baráth
authors.forename: Tünde
authors.initials: T
authors.lastname: Tarr
authors.forename: Margit
authors.initials: M
authors.lastname: Zeher
authors.forename: Sándor
authors.initials: S
authors.lastname: Sipka
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002117:Calcitriol / Q000494:pharmacology*; D016022:Case-Control Studies; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism*; D007527:Isoenzymes; D008180:Lupus Erythematosus, Systemic / Q000201:enzymology* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011493:Protein Kinase C / Q000378:metabolism*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; C508594:IL2 protein, human; D007376:Interleukin-2; D007527:Isoenzymes; D011493:Protein Kinase C; D002117:Calcitriol